TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03912740
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups will have remifentanil analgesia guided by the Nol-Index
Study: NCT00508911
Drug: GW876008
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
Study: NCT02735577
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
Study: NCT00039390
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO)
Study: NCT03704675
Drug: TEW-7197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00490971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
Study: NCT03829475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is an infusion of normal saline.
Study: NCT04500249
Drug: infiltration rescue intraoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
Study: NCT04500249
Drug: rescue antyhypertensive medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
Study: NCT04500249
Drug: rescue antyemetic medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
Study: NCT04500249
Drug: rescue antyhypotensive medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
Study: NCT04500249
Drug: rescue antyhypotensive medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
Study: NCT01628562
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.5 mcg/kg/min
Study: NCT02789969
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1.5mcg/kg IV
Study: NCT01775423
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02007720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02440061
Drug: Synthetic human AG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
Study: NCT02440061
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine hydrochloride (5 g) intravenously over 45 seconds.
Study: NCT02440061
Drug: 0.9% saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
Study: NCT02590900
Drug: intravenous paracetamol (acetaminophen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
Study: NCT00957177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02021461
Drug: ESL Tutti-Frutti taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study: NCT00250172
Drug: [C-11](R)-rolipram
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02898077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02703181
Drug: Placebo to match GSK557296
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
Study: NCT01419535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
Study: NCT01461733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo delivered blinded
Study: NCT02939209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may be randomized to placebo.
Study: NCT02240459
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
Study: NCT02876796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule(s) administered orally
Study: NCT02823470
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
Study: NCT01194375
Drug: Low Strength IDP-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 16 weeks
Study: NCT01194375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 16 weeks
Study: NCT00027547
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00841217
Drug: GW501516
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg/day
Study: NCT00841217
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01278602
Drug: R-ESHAP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
Study: NCT03450759
Drug: AZD9977 Oral suspension (reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
Study: NCT03450759
Drug: AZD9977 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
Study: NCT03450759
Drug: AZD9977 ER capsule (Int. rate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Study: NCT01223404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered a placebo patch and a placebo capsule
Study: NCT04999618
Drug: Haemoblock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivering with transdermal patches
Study: NCT01814410
Drug: Intravenous ethanol placebo plus nicotine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study: NCT01814410
Drug: intravenous ethanol 40mg% plus nicotine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study: NCT01814410
Drug: intravenous ethanol 100mg% plus nicotine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study: NCT01697800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02467361
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
Study: NCT02360774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Study: NCT01511783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
Study: NCT00017368
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017368
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03248882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02630563
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
Study: NCT03476759
Drug: IVF/ICSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 patients will undergo IVF-ICSI procedures.
Study: NCT00319709
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01150578
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention
Study: NCT00416819
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416819
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01773083
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
Study: NCT03865927
Drug: GKT137831
Approvals — FDA: no, EMA: no, PMDA: no
Description: GKT137831 is a NOX enzyme inhibitor
Study: NCT04101383
Drug: RinGlar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
Study: NCT04101383
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
Study: NCT00245024
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02244047
Drug: Placebo (for Bifidobacterium breve)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00789620
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
Study: NCT01249417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. injection on day 1 of a single treatment cycle.
Study: NCT02760719
Drug: nebulized 3% hypertonic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: already described
Study: NCT04365231
Drug: Hydroxychloroquine and azithromycin treatment
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.
Study: NCT00360425
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427141
Drug: GSK580416
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00872521
Drug: PAD induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)
Study: NCT02309970
Drug: acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: subject in this group will receive oral treatment with anti platelet drug
Study: NCT03744637
Drug: MK-5475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
Study: NCT03744637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single inhaled dose of placebo to match MK-5475
Study: NCT02871141
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant
Study: NCT02893384
Drug: Local Anesthetic Injection above the serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
Study: NCT01064414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
Study: NCT02361112
Drug: pyrotinib combined with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03131167
Drug: SHP639 (n=60)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
Study: NCT03131167
Drug: Placebo Comparator (n=24)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
Study: NCT01167569
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
Study: NCT00002610
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002610
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01018238
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
Study: NCT03428100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03428100
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as standard-of-care.
Study: NCT03861780
Drug: Project X 26ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study: NCT03861780
Drug: Project X 5.1ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal and abdomen areas of the subjects
Study: NCT02884310
Drug: Remifentanil adapted to SPI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02884310
Drug: Remifentanil fixed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00750763
Drug: Colonlytely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation
Study: NCT00750763
Drug: Picolax/Picoprep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation
Study: NCT02532335
Drug: Obeticholic acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT03746587
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule
Study: NCT04351165
Drug: IMP4297
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP4297 10mg/capsule; IMP4297 20mg/capsule;
Study: NCT02221648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomization to receive either the study drug or the placebo group.
Study: NCT00371956
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tab 1 daily
Study: NCT01222000
Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
Approvals — FDA: no, EMA: no, PMDA: no
Description: After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
Study: NCT02711176
Drug: Tinafas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
Study: NCT02711176
Drug: Tavanex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
Study: NCT03878992
Drug: Genotropin miniquick 0.5 mg, injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
Study: NCT02711176
Drug: Klacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
Study: NCT02711176
Drug: Iramox
Normalized name: pramoxine hydrochloride Topical Gel [Pramox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
Study: NCT03639246
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD is active comparator
Study: NCT00807885
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
Study: NCT00062348
Drug: boronophenylalanine-fructose complex
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02236312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00327717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
Study: NCT00719160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg twice a day for 9 days
Study: NCT03059693
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01954238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
Study: NCT01211145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT01205347
Drug: Simvastatin 80mg
Normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80mg once a day
Study: NCT01205347
Drug: Simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 10mg once a day
Study: NCT01518569
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (the same amount of normal saline) iv before the initiation of CPB
Study: NCT00625456
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
Study: NCT01373151
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
Study: NCT01373151
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks
Study: NCT01373151
Drug: Methotrexate Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Study: NCT01373151
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Study: NCT00361452
Drug: nebulized epinephrine and nebulized albuterol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190813
Drug: Levodopa/Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid